Elicio Therapeutics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.43
- 52-Week Range
- $1.25 – $16.00
- Market Cap
- $45.01M
- P/E (TTM)
- —
- EPS (TTM)
- -1.81
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.39
- PEG Ratio
- —
- Return on Equity
- -315.32%
- Return on Assets
- -70.58%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 3.43
- Debt/Equity
- 0.74
- Total Debt
- $13.99M
- Free Cash Flow
- $-21.18M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $28.10M
Market Snapshot
About
Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The company's proprietary Amphiphile (AMP) platform technology is designed to direct immune responses to lymph nodes, where T cells are activated. Elicio's lead programs focus on cancer vaccines and immunomodulatory therapies that aim to generate robust and durable anti-tumor immune responses. The company is conducting clinical trials in multiple cancer types, including pancreatic cancer and other solid tumors with significant unmet medical needs.